BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36420687)

  • 1. Somatic mutations in tumor and plasma of locoregional recurrent and/or metastatic head and neck cancer using a next-generation sequencing panel: A preliminary study.
    Rapado-González Ó; Brea-Iglesias J; Rodríguez-Casanova A; Bao-Caamano A; López-Cedrún JL; Triana-Martínez G; Díaz-Peña R; Santos MA; López-López R; Muinelo-Romay L; Martínez-Fernández M; Díaz-Lagares Á; Suárez-Cunqueiro MM
    Cancer Med; 2023 Mar; 12(6):6615-6622. PubMed ID: 36420687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liquid biopsy for mutational profiling of locoregional recurrent and/or metastatic head and neck squamous cell carcinoma.
    Galot R; van Marcke C; Helaers R; Mendola A; Goebbels RM; Caignet X; Ambroise J; Wittouck K; Vikkula M; Limaye N; Machiels JH
    Oral Oncol; 2020 May; 104():104631. PubMed ID: 32169746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next-generation sequencing (NGS) profiling of matched tumor and circulating tumor DNA (ctDNA) in head and neck squamous cell carcinoma (HNSCC).
    Economopoulou P; Spathis A; Kotsantis I; Maratou E; Anastasiou M; Moutafi MK; Kirkasiadou M; Pantazopoulos A; Giannakakou M; Edelstein DL; Sloane H; Fredebohm J; Jones FS; Kyriazoglou A; Gavrielatou N; Foukas P; Panayiotides I; Psyrri A
    Oral Oncol; 2023 Apr; 139():106358. PubMed ID: 36871349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a Targeted Next-Generation Sequencing Panel for the Non-Invasive Detection of Variants in Circulating DNA of Colorectal Cancer.
    Rodríguez-Casanova A; Bao-Caamano A; Lago-Lestón RM; Brozos-Vázquez E; Costa-Fraga N; Ferreirós-Vidal I; Abdulkader I; Vidal-Insua Y; Rivera FV; Candamio Folgar S; López-López R; Muinelo-Romay L; Diaz-Lagares A
    J Clin Med; 2021 Sep; 10(19):. PubMed ID: 34640513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Saliva-based cell-free DNA and cell-free mitochondrial DNA in head and neck cancers have promising screening and early detection role.
    Sayal L; Hamadah O; Almasri A; Idrees M; Thomson P; Kujan O
    J Oral Pathol Med; 2023 Jan; 52(1):29-36. PubMed ID: 36459078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma cell-free DNA methylome profiling in pre- and post-surgery oral cavity squamous cell carcinoma.
    Patel KB; Padhya TA; Huang J; Hernandez-Prera JC; Li T; Chung CH; Wang L; Wang X
    Mol Carcinog; 2023 Apr; 62(4):493-502. PubMed ID: 36636912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of genetic variants of frequently mutated genes in human papillomavirus-negative primary head and neck squamous cell carcinoma, resection margins, local recurrences and corresponding circulating cell-free DNA.
    Flach S; Kumbrink J; Walz C; Hess J; Drexler G; Belka C; Canis M; Jung A; Baumeister P
    J Oral Pathol Med; 2022 Sep; 51(8):738-746. PubMed ID: 35895622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FAT1 somatic mutations in head and neck carcinoma are associated with tumor progression and survival.
    Lin SC; Lin LH; Yu SY; Kao SY; Chang KW; Cheng HW; Liu CJ
    Carcinogenesis; 2018 Dec; 39(11):1320-1330. PubMed ID: 30102337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatic mutations in plasma cell-free DNA are diagnostic markers for esophageal squamous cell carcinoma recurrence.
    Ueda M; Iguchi T; Masuda T; Nakahara Y; Hirata H; Uchi R; Niida A; Momose K; Sakimura S; Chiba K; Eguchi H; Ito S; Sugimachi K; Yamasaki M; Suzuki Y; Miyano S; Doki Y; Mori M; Mimori K
    Oncotarget; 2016 Sep; 7(38):62280-62291. PubMed ID: 27556701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The genomic architectures of tumour-adjacent tissues, plasma and saliva reveal evolutionary underpinnings of relapse in head and neck squamous cell carcinoma.
    Wu P; Xie C; Yang L; Liu Y; Zeng J; Li X; Fang X; Fan Y; Zhao S; Kuang N; Xuan T; Xia X; Yi X; Huang Y; Yu Z; Tang Y
    Br J Cancer; 2021 Sep; 125(6):854-864. PubMed ID: 34230611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma.
    Chau NG; Li YY; Jo VY; Rabinowits G; Lorch JH; Tishler RB; Margalit DN; Schoenfeld JD; Annino DJ; Goguen LA; Thomas T; Becker H; Haddad T; Krane JF; Lindeman NI; Shapiro GI; Haddad RI; Hammerman PS
    Clin Cancer Res; 2016 Jun; 22(12):2939-49. PubMed ID: 26763254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-platform comparison of next-generation sequencing and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for detecting KRAS/NRAS/BRAF/PIK3CA mutations in cfDNA from metastatic colorectal cancer patients.
    Xu X; Huang F; Cao M; Chen X; Wang H; Jiang H; Yu Y; Shen M; Yang Y; Wang B; Liu T; Guo W
    J Clin Lab Anal; 2021 Sep; 35(9):e23818. PubMed ID: 34403504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
    Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
    Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting therapeutic responses in head and neck squamous cell carcinoma from
    Wei M; Zhi J; Li L; Wang W
    Transl Cancer Res; 2023 Dec; 12(12):3604-3617. PubMed ID: 38197078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of DNA methylation levels of
    Grossi I; Assoni C; Lorini L; Smussi D; Gurizzan C; Grisanti S; Paderno A; Mattavelli D; Piazza C; Pelisenco IA; De Petro G; Salvi A; Bossi P
    Oncol Rep; 2024 Mar; 51(3):. PubMed ID: 38299234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical determinants for successful circulating tumor DNA analysis in prostate cancer.
    Schweizer MT; Gulati R; Beightol M; Konnick EQ; Cheng HH; Klemfuss N; De Sarkar N; Yu EY; Montgomery RB; Nelson PS; Pritchard CC
    Prostate; 2019 May; 79(7):701-708. PubMed ID: 30865311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salivary microRNA miR-let-7a-5p and miR-3928 could be used as potential diagnostic bio-markers for head and neck squamous cell carcinoma.
    Fadhil RS; Wei MQ; Nikolarakos D; Good D; Nair RG
    PLoS One; 2020; 15(3):e0221779. PubMed ID: 32208417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
    van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
    Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Prognostic and Therapeutic Value of the Mutational Profile of Blood and Tumor Tissue in Head and Neck Squamous Cell Carcinoma.
    Wilson HL; D'Agostino RB; Meegalla N; Petro R; Commander S; Topaloglu U; Zhang W; Porosnicu M
    Oncologist; 2021 Feb; 26(2):e279-e289. PubMed ID: 33098199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of clinically relevant somatic mutations in high-risk head and neck cutaneous squamous cell carcinoma.
    Zilberg C; Lee MW; Yu B; Ashford B; Kraitsek S; Ranson M; Shannon K; Cowley M; Iyer NG; Palme CE; Ch'ng S; Low TH; O'Toole S; Clark JR; Gupta R
    Mod Pathol; 2018 Feb; 31(2):275-287. PubMed ID: 28984303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.